More recently, an extensive report from Ahfeldt et al. (74) used hMO to study the roles of 3 severe PD-associated mutations (in PRKN/PARK2, DJ1/PARK7, and ATP13A2/PARK9) through genomic editing of a healthy control hiPSC line. Here, PRKN is linked to Parkinson disease.